Search Results
Your search for ,cEO matches 438 pages
Showing 401 - 438Michael Reney, MBA, Named CFO at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has named Michael Reney, MBA, its Chief Financial Officer (CFO), where he will be responsible for all financial operations, including accounts payable, financial planning and reporting, payroll, capital asset management, tax, and general and patient accounting....
California Agency Invests $20 Million in Clinical Trial for Glioblastoma Vaccine
California’s Stem Cell Agency (CIRM) has awarded $19.9 million to ImmunoCellular Therapeutics to carry out a phase III clinical trial in patients with newly diagnosed glioblastoma using an immunotherapeutic vaccine. “This kind of deadly disease is precisely why we created CIRM 2.0, our new...
Three Young Investigators Named Winners of 2015 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSKCC) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research. The winners are Bradley E. Bernstein, MD,...
The Future of ASCO: President-Elect Candidates Share Their Vision
S. Gail Eckhardt, MD, FASCO, is a tenured Professor at the University of Colorado School of Medicine, where she also holds the Stapp Harlow Chair in Cancer Research. She has been a faculty member at the institution since 1999 and was Division Head of Medical Oncology from 2006–2014. Currently, she...
A Blueprint for Drug/Diagnostic Development: Expansion and Use of Curated Genetic Databases
In a continuation of a 2014 conference that explored regulatory considerations and strategies for next-generation sequencing, the Friends of Cancer Research, with support from Alexandria Real Estate Equities, Inc, Pasadena, California, met to discuss the issues and problems of coordinating drug and ...
Cancer Care in Low-Resource Areas: Some Improvements Over the Years, but Serious Problems Remain
Low- and middle-income countries bear a larger share of the global cancer burden than does the developed world,” said Greta Massetti, PhD, Associate Director for Science, Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control and Co-Chair of the National Cancer...
Making a Difference for Patients: An Interview With Dr. Daniel F. Hayes, 2015–2016 President-Elect
Daniel F. Hayes, MD, FASCO, began his term as ASCO President-Elect this past June, and will serve as President in 2016–2017. A breast cancer specialist, he is Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at ...
NCCN Foundation Appoints Three New Representatives to Board of Directors
The National Comprehensive Cancer Network (NCCN) Foundation has appointed three new representatives to its Board of Directors: Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH. There are currently 15 members of the Board of Directors, responsible for the strategic direction...
NCCN Names Robert C. Young, MD, Interim Vice President of Oncology Research Program
The National Comprehensive Cancer Network (NCCN) has appointed Robert C. Young, MD, as Interim Vice President of the NCCN Oncology Research Program. Dr. Young brings to NCCN more than 45 years of oncology experience. He is President of RCY Medicine, a consulting service focused on cancer center...
West Cancer Center Opens East Campus Location
West Cancer Center celebrated the grand opening of its East Campus location with a ribbon-cutting ceremony on November 17th. Located at 7945 Wolf River Boulevard in Memphis, Tennessee, the 123,000 square foot facility combines multispecialty services including medical, surgical, diagnostic, and...
Drew Ridge, MD, PhD, FACS, Elected to Medical Staff President at Fox Chase Cancer Center–Temple Health
John Andrew “Drew” Ridge, MD, PhD, FACS, Chief of Head and Neck Surgery and Louis Della Penna Family Chair in Head and Neck Oncology at Fox Chase Cancer Center–Temple Health, has been elected President of the Medical Staff at the Center. In his new role, Dr. Ridge will work with President and CEO...
Perceptions of End-of-Life Care Differ Sharply Between African Americans and White Americans
Studies demonstrate that patients with advanced cancer who are not actively engaged in planning their end-of-life care often receive overly aggressive, physically taxing, costly and unnecessary treatment toward life’s end. Recent findings indicate that African Americans appear to be more apt to...
St. Jude Names Carlos Rodriguez-Galindo, MD, Director of International Outreach Program
Carlos Rodriguez-Galindo, MD, an international leader in pediatric solid tumor research, is joining St. Jude Children’s Research Hospital to head the International Outreach Program. Dr. Rodriguez-Galindo will serve as International Outreach Program Director and an executive vice president. He will...
Jonathan S. Lewin, MD, Joins Emory University
Emory University announced that Jonathan S. Lewin, MD, has been appointed Executive Vice President for Health Affairs. Dr. Lewin also will serve as Executive Director for Emory’s Woodruff Health Sciences Center, President and CEO of Emory Healthcare and Chair of the Board of Directors of Emory...
ASH 2015: American Society of Hematology Releases Compilation of Top Choosing Wisely Recommendations Relevant to Hematology
The American Society of Hematology (ASH) has released a list of five hematology-related tests and procedures to question based on recommendations from other medical societies taking part in the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign. This list...
Statement From AACR CEO Margaret Foti, PhD, MD (hc), on Vice President Biden’s Call for More Cancer Research
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), issued the following statement regarding Vice President Joe Biden’s call for a “moon shot” to end cancer: “We extend our deepest sympathy to Vice President Biden and his family for the...
NCCN Unveils Evidence Blocks for CML and Multiple Myeloma
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 26 of the world's leading cancer centers, has unveiled its new value initiative—the NCCN Evidence Blocks, published within new versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for...
Pancreatic Cancer Action Network and AACR Invite Applications for 2016 Research Grants
The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...
Study Finds Modified CAR T Cells Can Selectively Target Solid Tumor Cells While Sparing Healthy Cells
Chimeric antigen receptor (CAR) T cells that are currently being tested to treat B-cell malignancies target a specific protein present on leukemia and lymphoma cells, but these immune cells cannot distinguish the cancer cells from healthy cells. However, the side effects from these CAR T cells...
Treatment With PI3K Inhibitors May Cause Cancers to Become More Aggressive and Metastatic
The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only ...
New Molecular Diagnostic Test Predicts Progression of Barrett's Esophagus to Esophageal Cancer
Interpace Diagnostics, a subsidiary of PDI, Inc, announced new data demonstrating the clinical value of BarreGen, a molecular diagnostic test that predicts the risk of progression from Barrett’s esophagus to esophageal cancer approximately 3 to 4 years before the cancer develops. These...
Human Reovirus Formulation Receives FDA Orphan Drug Designation for Fallopian Tube Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of fallopian tube cancer. The designation was granted on the basis of the company's December 2014 application for ...
FDA Grants Priority Review to Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to Ipsen’s supplemental New Drug Application (sNDA) for the somatostatin analog lanreotide (Somatuline Depot) 120 mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. The FDA...
FDA Grants Orphan Drug Designation to Mocetinostat for Diffuse Large B-Cell Lymphoma
The U.S. Food and Drug Administration has granted Orphan Drug Designation to Mirati Therapeutics’ mocetinostat, a spectrum-selective HDAC inhibitor, for diffuse large B-cell lymphoma. In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome....
St. Jude Children’s Research Hospital Appoints James R. Downing, MD, as CEO
St. Jude Children’s Research Hospital announced the appointment of James R. Downing, MD, as its new CEO, effective July 15, 2014. Dr. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital. He succeeds William E. Evans,...
Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for CLL
In response to FDA's approval earlier this week of ibrutinib (Imbruvica) to treat patients with chronic lymphocytic leukemia (CLL) who had received at least one prior therapy, The Leukemia & Lymphoma Society (LLS) issued the following statement: "After the FDA designated ibrutinib as a...
Interim Phase I/II Clinical Trial Data for VAL-083 Show Clinical Activity in Refractory Glioblastoma
Interim phase I/II clinical trial data for VAL-083—a bifunctional DNA alkylator that crosses the blood-brain barrier with preferential accumulation in brain tumor tissue—in patients with recurrent glioblastoma multiforme were presented by Shih et al at the 4th Quadrennial Meeting of the ...
Myeloma Foundation Launches Open Access Gateways to Accelerate Drug Development
The Multiple Myeloma Research Foundation (MMRF) has announced two open access gateways, the MMRF Researcher Gateway, which will upload genomic data as it becomes available and make it accessible to all researchers, and the MMRF CoMMunity Gateway, which will aggregate subtypes of myeloma patients...
Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Center
Richard I. Fisher, MD, a leading cancer center administrator and nationally recognized hematology/oncology expert, has been appointed President and CEO of Fox Chase Cancer Center. Dr. Fisher will also hold the title of Cancer Center Director of Fox Chase, serving as the principal investigator on...
Cancer Organizations Provide Support for Required Cancer Center Distress Screening Programs
The American Psychosocial Oncology Society (APOS) has announced recommendations to support a new criterion for cancer center accreditation. In 2015, the American College of Surgeons (ACoS) Commission on Cancer (CoC) will require cancer centers to implement screening programs for...
New Drug Application Submitted for Ibrutinib in the Treatment of Two B-cell Malignancies
Pharmacyclics, Inc, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma (MCL) and...
Human Genes May Not Be Patented, Rules the Supreme Court
The U.S. Supreme Court ruled unanimously on Thursday that isolated human genes may not be patented. However, the creation of synthetic forms of DNA, known as complementary DNA (cDNA), is eligible for patent protection. The decision resolves the question brought before the Supreme Court justices in...
ASCO Completes Prototype for CancerLinQ™, Marking First Demonstration of a “Learning Health System” to Transform Cancer Care
The American Society of Clinical Oncology announced yesterday that it has completed a prototype of CancerLinQ™, the Society’s groundbreaking health information technology (HIT) initiative to achieve higher quality, higher value cancer care with better outcomes for patients. The...
Highlights of the NCCN 18th Annual Conference Include Expert Roundtables, Presentation of New Guidelines for Survivorship
The National Comprehensive Cancer Network (NCCN) held the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™, March 13-17, 2013, at The Westin Diplomat in Hollywood, Florida. The latest updates in clinical practice decision-making in cancer care were presented, including, but ...
NCCN Adds Two New Member Institutions
The National Comprehensive Cancer Network (NCCN) announced today the addition of two new NCCN Member Institutions: UC San Diego Moores Cancer Center in La Jolla, California, and the University of Colorado Cancer Center in Aurora, Colorado. "We are extremely pleased that UC San Diego Moores Cancer...
Samuel M. Silver, MD, PhD, Elected Chairman of NCCN Board of Directors
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, has been elected Chairman of the National Comprehensive Cancer Network (NCCN) Board of Directors. Dr. Silver was previously Vice Chairman of the Board and succeeds Thomas A. D'Amico, MD, of the Duke Cancer...
Inaugural Winners of the Breakthrough Prize in Life Sciences Announced
Founding sponsors Art Levinson, PhD, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner announced the launch of the Breakthrough Prize in Life Sciences, recognizing excellence in research aimed at curing intractable diseases and extending human life. The prize will be...
New Website Raises Awareness of Uveal Melanoma and the Importance of Prognostic Testing
Launch of a website created to educate newly diagnosed patients, their families, and health-care providers about uveal melanoma, was announced recently by Castle Biosciences, Inc, a developer of prognostic tests for rare cancers. The website, MyUvealMelanoma.com, addresses the treatment of uveal...
